All In Biotech

Drug Trial Radar · NCT03075267

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days

Last checked: Nov 20, 2026Latest source record: Jan 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Apr 17, 2017

Primary completion

Sep 5, 2017

Study completion Sep 5, 2017

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of PT003 in healthy Chinese adult subjects

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • PT010 (BGF MDI) 320/14.4/9.6 µgDrug

    A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

  • PT010 (BGF MDI) 160/14.4/9.6 µgDrug

    A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

  • PT003 (GFF MDI) 14.4/9.6 µgDrug

    A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  2. Maximum Plasma Concentration (Cmax) - BudesonideTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  3. Maximum Plasma Concentration (Cmax) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  4. Maximum Plasma Concentration (Cmax) - GlycopyrroniumTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  5. Maximum Plasma Concentration (Cmax) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  6. Maximum Plasma Concentration (Cmax) - FormoterolTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  7. Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  8. Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - BudesonideTime frame: Day 8
  9. Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - GlycopyrroniumTime frame: Day 1
  10. Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - GlycopyrroniumTime frame: Day 8
  11. Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - FormoterolTime frame: Day 1
  12. Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - FormoterolTime frame: Day 8
  13. Time to Maximum Plasma Concentration (Tmax) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  14. Time to Maximum Plasma Concentration (Tmax) - BudesonideTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  15. Time to Maximum Plasma Concentration (Tmax) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  16. Time to Maximum Plasma Concentration (Tmax) - GlycopyrroniumTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  17. Time to Maximum Plasma Concentration (Tmax) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  18. Time to Maximum Plasma Concentration (Tmax) - FormoterolTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  19. Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - BudesonideTime frame: Day 1
  20. Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - GlycopyrroniumTime frame: Day 1
  21. Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - FormoterolTime frame: Day 1
  22. Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - BudesonideTime frame: Day 1
  23. Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - GlycopyrroniumTime frame: Day 1
  24. Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - FormoterolTime frame: Day 1
  25. Elimination Half-life (t½) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  26. Elimination Half-life (t½) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  27. Elimination Half-life (t½) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  28. Apparent Total Body Clearance (CL/F) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  29. Apparent Total Body Clearance (CL/F) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  30. Apparent Total Body Clearance (CL/F) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  31. Apparent Volume of Distribution (Vd/F) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  32. Apparent Volume of Distribution (Vd/F) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  33. Apparent Volume of Distribution (Vd/F) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  34. Terminal Elimination Rate Constant (λz) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  35. Terminal Elimination Rate Constant (λz) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  36. Terminal Elimination Rate Constant (λz) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  37. Accumulation Ratio for Cmax (RAC [Cmax]) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  38. Accumulation Ratio for Cmax (RAC [Cmax]) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
  39. Accumulation Ratio for Cmax (RAC [Cmax]) - FormoterolTime frame: Day 1 and Day 8
  40. Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - BudesonideTime frame: Day 1 and Day 8
  41. Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - GlycopyrroniumTime frame: Day 1 and Day 8
  42. Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - FormoterolTime frame: Day 1 and Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.